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Microglia have long been noted to be present and activated in Alzheimer brain. Demonstrations that these microglia are associated
with the speciﬁc lesions of Alzheimer disease—Aβ plaques and neuroﬁbrillary tangles—and that these microglia overexpress the
potent proinﬂammatory cytokine interleukin-1 led to the recognition of a potential pathogenic role for these cells in initiation and
progressionofdisease.Activated,cytokine-overexpressingmicrogliaarenear-universalcomponentsofAβ plaquesatearly(diﬀuse)
and mid (neuritic) stages of progression in Alzheimer brain, and only decline in end-stage, dense core plaques. They correlate with
plaque distribution across cerebral cortical cytoarchitectonic layers and across brain regions. They also show close associations
with tangle-bearing neurons in Alzheimer brain. Microglial activation is a consistent feature in conditions that confer increased
risk for Alzheimer disease or that are associated with accelerated appearance of Alzheimer-type neuropathological changes. These
includenormalageing,headinjury,diabetes,heartdisease,andchronicintractableepilepsy.Theneuropathologicaldemonstration
ofmicroglialactivationinAlzheimerbrainandinAlzheimer-relatedconditionsopenedtheﬁeldofbasicandappliedinvestigations
centered on the idea of a pathogenically important neuroinﬂammatory process in Alzheimer disease.
1.Introduction
Microgliahavebeenknowntobepresentinthecharacteristic
plaques of Alzheimer disease since the ﬁrst descriptions of
these cells by del Rio Hortega and Penﬁeld in the 1920s
[1], but half a century would pass before attention returned
to these cells. The ﬁrst suggestion of a causative role for
microglia in Alzheimer disease came from Glenner, who
hypothesized in 1979 that the amyloid found in Alzheimer
brain was produced by these cells [2]. This idea dominated
several subsequent studies that identiﬁed microglia associ-
atedwithamyloidplaquesinthebrainsofAlzheimerpatients
[3–5]. The idea was largely abandoned when the neuronal
origin of Aβ was elucidated [6], although occasional studies
have returned to this idea [7].
The ﬁrst evidence that microglia may have an immu-
nological—rather than a phagocytic or Aβ-processing—
function in Alzheimer brain was the demonstration in 1989
by Griﬃn and colleagues that these microglia express
the potent immunomodulatory cytokine interleukin-1 [8]
(Figure 1). This report, together with the ﬁnding that
interleukin-1 regulates the synthesis of the Aβ precursor
protein [9], immediately suggested that microglia and their
cytokines might play a role in driving plaque development, a
concept very diﬀerent from ideas about amyloid production
or phagocytosis and protein degradation that had been pre-
viously attributed to microglia. Over the next several years,
additionalcytokineswereaddedtothelistingofproteinsthat
are elevated in Alzheimer brain. These include interleukin-
6[ 10], transforming growth factor β1 [11], interferon α
[12, 13], and interleukins-2 and -3 [14].
Ideasregarding theroleofmicroglia inAlzheimerdisease
havecontinuedtoevolveoverthe20yearssincetheseseminal
studies. Neuropathological investigations, in particular, have
both suggested and supported ideas about the potential roles
of inﬂammatory mechanisms in Aβ plaque formation and
progression in Alzheimer disease, and the potential roles of
microglial activation in progressive plaque-associated neu-
ritic damage, neuronal damage, and neuronal death. This
review will highlight these neuropathological studies.
2.MicroglialIdentiﬁcation inHumanBrain
Microglia were ﬁrst described in 1899 by Nissl, who distin-
guished these cells from other neural components based on2 International Journal of Alzheimer’s Disease
the shape of their nuclei [15]. The deﬁnitive identiﬁcation
and characterization of these cells were done in the 1920s
by del Rio Hortega and Penﬁeld, using a silver carbonate
staining technique [1]. Microglia are now known to express
a wide variety of immune-related molecules and antigens
[16], many of which can be used to immunolabel microglia
in histological tissue sections. “Resting” microglia, found
throughoutnormalbrainparenchyma,expressmanyofthese
molecules either at very low levels or not at all.
In contrast to the low levels of expression of immune-
related molecules by resting microglia, immunological chal-
lenge or tissue injury leads to upregulation of many of these
factors, a process known as microglial activation. With fur-
ther activation, microglia undergo morphological changes
that include enlargement and withdrawal of their ramiﬁed
processes.Activatedmicrogliacanbeidentiﬁedthroughtheir
expression of such factors. In general, however, antibodies
against secreted products such as interleukin-1β (IL-1β)
or tumor necrosis factor-α generally yield poor results in
paraﬃn sections as these soluble peptides are lost dur-
ing tissue processing. In contrast, the cytokine IL-1α is
expressed by microglia as a membrane-bound peptide, and
immunohistochemistry using antibodies against IL-1α is
very eﬀective at labeling activated microglia while producing
little or no labeling of resting microglia (Figure 1)[ 17].
Other techniques that have been used to identify microglia
include MHC class II cell surface receptors [18], Fc receptors
[19], various lectins [20–22], and other monocyte markers
[23, 24]. More recently, immunohistochemistry for ion-
ized calcium binding adapter molecule 1 (Iba1) has been
identiﬁed as a reliable marker for microglia, although this
technique labels resting as well as activated microglia and
is thus not speciﬁc for activated forms [25, 26]. A subset of
microglia express ferritin and can be immunolabelled with
anti-ferritinantibodies.Suchexpression,however,appearsto
representadegenerative,or“dystrophic”changeinmicroglia
rather than an activated state [27].
3.MicroglialAssociationswithAβ Plaques
Activated microglia are near-universal components of Aβ
plaques in Alzheimer brain. In Alzheimer brain, microglia
accumulate fragmented DNA, presumably originating from
neuronal injury and death [28].Suchaccumulation,together
with cytokine stimulation, is a potent microglial activating
stimulus [28]. Microglial activation has been shown to
progress with clinical (CDR) stage of dementia [29, 30], with
neuropathological (Braak and Braak [31]) stage of disease
severity [29], and with stage of progression of individual
Aβ plaques [32]. The distribution of activated microglia
across diﬀerent brain regions closely parallels that of neuritic
plaques in Alzheimer brain, with involvement of hip-
pocampus > temporal lobe > frontal and occipital lobes
[33]. Moreover, there is variation in the distribution of
microglia in diﬀerent cortical cytoarchitectonic layers [34].
In Alzheimer brain, this distribution correlates closely with
the distribution of neuritic plaques across these same layers,
with both showing greater involvement of layers III–VI than
Figure 1: Activated microglia, overexpressing interleukin-1, within
an Aβ plaque in Alzheimer brain. Immunohistochemistry using an
antibody speciﬁc for IL-1α.
of layers I-II. Of even greater interest, normal individuals—
without Alzheimer disease and without neuritic plaques—
show a similar (but much less pronounced) variation in
content of (resting) microglia across these cortical layers.
This latter ﬁnding suggests that the normal distribution of
microglia across cerebral cortical layers may inﬂuence the
pattern of development of neuritic plaques in Alzheimer
brain [34].
The association of activated microglia with Aβ plaques
is also a function of plaque type. The Aβ plaques present in
Alzheimer brain show diﬀerent morphological appearances,
whicharethoughttorepresentdiﬀerentstagesofplaquepro-
gression, commencing with diﬀuse deposits of Aβ peptide,
progressing to complex plaques with congophilic amyloid
and with evidence of damage to neurons and their processes
(“dystrophic neurites”), and terminating in a dense core of
condensed amyloid without diﬀuse Aβ peptide and without
adjacentdystrophicneurites[32,35].Thisschemataiswidely
(but not universally [7]) accepted.
Both the numbers of microglia and the degree of acti-
vation of microglia vary with plaque type, or stage [32].
Early plaques in Alzheimer brain—those which contain
diﬀuse deposits of Aβ peptide without formation of true
(ﬁbrillar) amyloid and without evidence of neuritic injury—
already contain small numbers of microglia that overexpress
interleukin-1 (IL-1) [32]. These microglia are not enlarged
or phagocytic [36] and thus are easily mistaken for normal
“resting” microglia in the absence of speciﬁc immunohisto-
chemical demonstration of their cytokine upregulation [26].
Of interest is the fact that similar-appearing diﬀuse deposits
of Aβ peptide can sometimes be found, in the absence of the
later plaque forms and in the absence of clinical dementia.
Thisincludes occasionalotherwisenormal,cognitively intact
elderly individuals, and includes individuals with the disease
hereditary cerebral hemorrhage with amyloidosis (Dutch)
(HCHA-D), a disease that is characterized by extensive amy-
loid angiopathy and consequent cerebral hemorrhage. In
contrast to the ubiquitous presence of activated microglia
in diﬀuse plaques present in Alzheimer brain [32], activatedInternational Journal of Alzheimer’s Disease 3
microglia have not been identiﬁed in either the similar-
appearing deposits in the brains of neurologically normal
elderly individuals [37] or in the similar-appearing deposits
in the brains of patients with HCHA-D [23]. This observa-
tionsuggeststhatAβ depositionaloneisnotsuﬃcientforthe
development of Alzheimer disease. Further, this observation
suggests that activated microglia, overexpressing IL-1, may
be a key element in Aβ plaque progression, and hence a key
element in the clinical conversion to, and progression of,
clinical Alzheimer disease.
It remains unclear why the diﬀuse Aβ deposits in normal
elderly or in HCHA-D diﬀer in their ability to attract and
activate microglia. One possibility is the lack of some code-
posited, immunogenic protein, possibly originating outside
the brain. In support of this idea is the observation that
Alzheimer brain shows diﬀuse immunoreactivity for the
serum-derived proteins ﬁbrinogen and IgG, suggesting
breakdown of blood-brain barrier function in Alzheimer
disease [38]. This ﬁbrinogen immunoreactivity is enhanced
in Aβ deposits and is associated with microglial activation
[38]. A second possibility is that there is a diﬀerence in some
physical characteristic of the Aβ peptide (e.g., oligomer or
ﬁbrillar state), as may be the case for patients with HCHA-D.
Finally, for those unusual elderly individuals with only
diﬀuse Aβ deposits, there is the third possibility that there
is an inherent diﬀerence in the responsiveness of microglia in
these individuals.
Early, diﬀuse plaques progress to neuritic forms, char-
acterized by condensation of Aβ peptide into true, ﬁbrillar
amyloid, and by the appearance of injured (dystrophic)
neural processes (neurites). At this stage, there are increases
both in the number of microglia associated with individual
plaques, and in the degree of activation of these associated
microglia [32, 36, 39]. In addition to overexpression of
IL-1, these microglia become enlarged with fewer ramiﬁed
processes, thus meeting classic morphological criteria (in
addition to immunohistochemical criteria) for activation.
With continued condensation of Aβ peptide, a “dense core”
ofamyloidisformed.Thisprocessappearstomaskorreverse
the immunogenic properties of the plaque, as the numbers
of microglia associated with such plaques are less than that
seen prior to the formation of the dense core [32]. Further,
the microglia found in these cored plaques are phagocytic
in appearance [36], although the appearance of microglia in
theselaterplaqueshasalsobeeninterpretedasadegenerative
or senescent change [26]. Microglia are clearly capable of
phagocytosingandevenremovingAβ,astrialsofAβvaccines
have suggested in both animals and humans [40].
The ﬁnal, end-stage of plaque progression is a solitary
dense core of amyloid, without surrounding diﬀuse Aβ pep-
tide and without associated dystrophic neurites. These end-
stageplaquesarealsodevoidofmicroglia,suggestingthatthe
immunogenic stimulus that attracts and activates microglia
has abated [32]. This waxing and waning of numbers of
activatedmicrogliawithplaqueprogressionhasitsparallelin
the ﬁnding that microglia in Alzheimer brain appear early in
the disease course (as measured by premortem assessments
using the Blessed test score) and decline late in the disease
[41], at which point there is severe dementia from the
accumulated neuronal loss. A similar observation is that
there is a slight decrease in microglial activation in end-stage
(Braak and Braak stage VI) Alzheimer brain, after showing
increases over the ﬁrst ﬁve Braak and Braak stages [42].
The concurrent absence of microglia and dystrophic
neurites in end-stage, dense-core plaques also suggests that
plaque-associated microglia may play a role in damaging
surrounding neural elements and generating the dystrophic
neurites of Alzheimer amyloid plaques. Interleukin-1 is
known to be neurotoxic at high concentrations, as coculture
of lipopolysaccharide-activated microglia with primary rat
cortical neurons results in neuronal death, and this eﬀect is
attenuated in the presence of the naturally occurring IL-1
receptor antagonist IL-1ra [43]. In human brain, the associa-
tion of activated, IL-1-expressing microglia with Aβ plaques
correlates with histochemical evidence of progressive neu-
ronal damage, as assessed using the TUNEL technique [44].
Cortical neurons contained within or adjacent to Aβ plaques
frequently show TUNEL positivity, and the percentage of
such neurons that are positive by this technique increases
with plaque progression, reaching nearly 100% in end-stage
dense core plaques. Further, the total number of plaque-
associated neurons declines signiﬁcantly in such end-stage
plaques,suggestingthatthereisneuronaldeathandlossasso-
ciated with plaque progression [44]. Plaques are generally
much more numerous than tangles in Alzheimer brain, and
neuronal loss in Alzheimer brain has long been known to
exceed the incidence of neuroﬁbrillary tangles [45]. Thus,
such plaque-associated neuronal injury and loss, mediated at
least in part by microglia-derived cytokine overexpression,
may be a signiﬁcant—and perhaps even major—source of
neuronal loss in Alzheimer brain.
4.MicroglialAssociationswith
Neuroﬁbrillary Tangles
Neuropathological investigations have also oﬀered evidence
that microglia may be involved in the pathogenesis and pro-
gression of neuroﬁbrillary tangle formation. Just as there are
correlations between the distribution of activated microglia
and distribution of Aβ plaques in Alzheimer brain, so, too
are there correlations between the distribution of microglia
and the distribution of neuroﬁbrillary tangles [46]. Further,
and again as for Aβ plaques, a progressive association has
been shown between activated microglia and neuroﬁbrillary
tanglestage[47].Neuroﬁbrillarytanglescanbeclassiﬁedinto
diﬀerent stages, representing a pathological progression [47,
48]. In Alzheimer brain, there is a progressive association of
activated, IL-1-overexpressing microglia with neuroﬁbrillary
tangles across this spectrum of tangle progression [47]. In
vitrowork has shownthat IL-1 increases neuronal expression
of the tau-phosphorylating enzyme MAPK-p38 and also
increases the phosphorylation (activation) of this enzyme
[43].This,togetherwiththeneuropathologicalobservations,
suggests that neuron-associated microglia may be important
in driving or sustaining neuronal tangle formation in
Alzheimer disease.4 International Journal of Alzheimer’s Disease
5. MicrogliainOther
Neurodegenerative Diseases
Chronic microglial activation as a potentially neurotoxic
driving force is not likely to be restricted to Alzheimer dis-
ease. Following the seminal observations of microglial acti-
vation in Alzheimer brain, similar microglial activation has
been found in other chronic neurological diseases, including
amyotrophic lateral sclerosis, spinocerebellar ataxia, and
Huntington’s disease [49–52], and especially in diseases
characterized by α-synuclein pathology: Parkinson’s disease,
dementia with Lewy bodies, and multiple system atrophy.
Activated, cytokine-overexpressing microglia are found in
the substantia nigra of Parkinson patients (for reviews, see
references [53–55]). Activated microglia also show close
associations with inclusion-bearing neurons in dementia
with Lewy bodies [56] and with inclusion-containing oligo-
dendrocytes in multiple system atrophy [57]. These ﬁndings
suggest a common ﬁnal pathway of neuronal injury and loss
in a number of chronic neurodegenerative diseases [58].
6.OriginsofNeuroinﬂammatory Processes
Alzheimer disease, and Alzheimer-type neuropathological
changes, show important associations with a number of
otherconditions.Theseincludeageing,headinjury,diabetes,
heart disease, and epilepsy. All of these conditions have been
shown to enhance or accelerate microglial activation in the
brain. In normal human ageing, for instance, there is a
progressive increase in the numbers of activated microglia
overexpressing IL-1 [59]. This eﬀect may serve to lower the
threshold required to subsequently initiate disease [60]a n d
may thus explain in part the strong age association of
Alzheimer disease. Similarly, head injury results in activation
of microglia overexpressing IL-1, together with expression of
the Aβ precursor protein by neurons and neuronal processes
[61]. For patients with established Alzheimer disease, and
microglial activation, there is further enhancement of this
microglial activation in the presence of concurrent diabetes
[62] or heart disease [63]. Patients with chronic intractable
temporal lobe epilepsy or with HIV infection show increased
proinﬂammatory activation of microglia [64, 65], and both
of these conditions have been associated with acceler-
ated appearance of age-associated, Alzheimer-type “senile”
changes [66, 67]. Collectively, these ﬁndings suggest that
proinﬂammatory processes of various etiologies can con-
tribute to a summative inﬂammatory state—characterized
by microglial activation—that lowers the threshold and
increases the risk for the subsequent development of neu-
rodegenerative disease.
7. Conclusion
Microglial activation is a universal feature of Alzheimer
disease, as well as a number of other chronic neurodegen-
erative diseases. These microglia show speciﬁc patterns of
association with the neuropathological features of Alzheimer
disease, which collectively suggest a pathogenic role in driv-
ing the progression of such pathology. Further, microglial
activation is a prominent feature of several other conditions
that have been associated with increased risk for Alzheimer
disease or with accelerated appearance of Alzheimer-type
neuropathological changes.
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